Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 410-690-9 | CAS number: 103055-07-8 CGA 184699
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Neurotoxicity
Administrative data
Description of key information
Key value for chemical safety assessment
Effect on neurotoxicity: via oral route
Link to relevant study records
- Endpoint:
- neurotoxicity: sub-chronic oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 20 May 1991 to 25 Nov 1991
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- other: CFR 40 §158.82-7
- Qualifier:
- according to guideline
- Guideline:
- other: CFR 40 §798.6400
- Qualifier:
- according to guideline
- Guideline:
- EPA OTS 798.6050 (Neurotoxicity Screening Battery)
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 424 (Neurotoxicity Study in Rodents)
- Version / remarks:
- Draft Guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- other: FIFRA § 82-5
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- EPA OPPTS 870.6200 (Neurotoxicity Screening Battery)
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Tif:RAIf (SPF)
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: about 8 weeks.
- Weight at study initiation: 233 to 322 g.
- Housing: The animals were initially housed in groups of 5 in Macrolon cages type 4 with wire mesh tops and soft wood bedding. Upon weighing about 500 g animals were separated and housed in groups of 2 or 3.
- Diet: Pelleted, certified standard diet, ad libitum. All batches of the diet were assayed for nutritive ingredients and contaminant level by the manufacturer. Analytical results are available at the Animal Supply Office.
- Water: Tap water, ad libitum. Drinking water quality according to the specifications of the "Schweizerisches Lebensmittelbuch" (Ed. 1972 / Appendix B). Results of the routine chemical examination at source as conducted periodically by the water authority (Baudepartement des Kantons Basel, Abteilung Gewasserschutz) are available.
- Acclimation period: 2 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2
- Humidity (%): 55 ± 10
- Airchanges (per hour): 16- 20
- Photoperiod (hrs dark / hrs light): 12 / 12
IN-LIFE DATES: From: 20 May 1991 To: 25 Nov 1991 - Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Analytical verification of doses or concentrations:
- yes
- Remarks:
- Stability and homogeneity of the test article in the food has been assessed for previously conducted toxicity studies.
- Duration of treatment / exposure:
- 4 months
- Frequency of treatment:
- Continuously
- Dose / conc.:
- 5 ppm
- Remarks:
- Group 2. Dietary concentration equivalent to 0.255 mg/kg bw/day
- Dose / conc.:
- 25 ppm
- Remarks:
- Group 3. Dietary concentration equivalent to 1.22 mg/kg bw/day
- Dose / conc.:
- 100 ppm
- Remarks:
- Group 4. Dietary concentration equivalent to 5.43 mg/kg bw/day
- Dose / conc.:
- 500 ppm
- Remarks:
- Group 5. Dietary concentration equivalent to 27 mg/kg bw/day
- No. of animals per sex per dose:
- 10 males per dose group, and 10 males in Group 1 and 5 as recovery animals.
- Control animals:
- yes, plain diet
- Details on study design:
- Dose selection rationale
- Males I: 5 animals per group for evaluation of neurotoxicity, including clinical signs, neurology, motor activity, startle habituation, maze learning, and potentiation of pentylenetetrazol- induced seizures, and for neuropathology
- Males II: 5 animals per group for evaluation of neurotoxicity, including clinical signs, neurology, motor activity, startle habituation, maze learning, and potentiation of pentylenetetrazol- induced seizures, neuropathology, and for determination of tissue concentrations
- Males III: 5 animals per group for evaluation of reversibility after 2 months of recovery including neurotoxicity and neuropathology
- Males IV: 5 animals per group for evaluation of reversibility after 2 months of recovery including neurotoxicity, neuropathology, and determination of tissue concentrations - Observations and clinical examinations performed and frequency:
- - Mortality: twice daily, once on weekends and public holidays
- Clinical signs: observed daily except for weekends, reported once weekly
- Body weight: weekly during pre-test, treatment, and recovery periods
- Food consumption: weekly during pre-test, treatment, and recovery periods
- Concentration of test article: after termination of treatment and recovery in tissue periods - Neurobehavioural examinations performed and frequency:
- - Neurological investigations: pre-test and monthly during treatment and recovery periods
- Motor activity: pre-test and monthly during treatment and recovery periods
- Startle habituation: pre-test and monthly during treatment and recovery periods
- Maze test: at end of treatment and recovery periods
- Pentylenetetrazol potentiation: at end of treatment and recovery periods - Sacrifice and (histo)pathology:
- - Necropsy and neuropathology periods: after termination of treatment and recovery
- Statistics:
- - For each time point and parameter an univariate statistical analysis was performed.
- In general nonparametric methods were applied, to allow for non normal as well as normal data distribution. Bodyweight and food consumption data from each treated group was compared to the control group by Lepage's two-sample test. This test is a combination of Wilcoxon and Ansari- Bradley statistics, i.e. a combined test for location and dispersion. The Lepage test has a good power against the more general alternative that the distributions differ not only in location but also in dispersion. Increasing or decreasing trends in location from control to the highest dose group were tested by Jonckheere's test for ordered alternatives. This test is sensitive to monotone dose-related treatment effects. Motor activity data were analysed by parametric procedures» using log transformed data. The treated groups were compared to the control group by repeated T-tests, based on the pooled variance estimate. Group means were tested for a trend (linear by group number) from control to the highest dose group. Two-sided p-values are given in the statistics table. - Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- In the 500 ppm group, a single episode of fasciculations and clonic-tonic convulsions was observed each in one animal between weeks 13-18. There were no other compound-related clinical signs in the treated animals.
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- There were no treatment-related mortalities during the study.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Mean body weight was comparable for all groups over the whole study period.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- Food consumption was comparable for all groups over the whole study period.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Endocrine findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- The maze learning error scores did not differ between controls and treated groups neither at the end of the treatment period nor at the end of the recovery period. Mean error score is a measure for complex memory and primarily depends on intact function of the hippocampus. Percent blind alley visits is a simple left-right discrimination involving long-term memory functions. The brain structures supporting this function have not yet been identified. These two measures cover cognitive functions that are also involved in complex learning tasks in humans.
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No treatment-related macroscopic or microscopic changes were seen in the central and peripheral nervous system and in muscles.
- Neuropathological findings:
- no effects observed
- Description (incidence and severity):
- - Motor activity parameters were not affected in any dose group throughout the whole study period.
- Mean peak amplitude (mean of first 10 startle reactions) and mean startle habituation (mean of first 10 – mean of last 10 startle reactions) were comparable for all dose groups throughout the whole study period. - Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- - At the end of treatment period as well as following the treatment-free recovery period perfusion fixation was performed on all animals on study.
- Macroscopic examination did not show any treatment-related changes in the tissues collected for processing.
- Light microscopic examination was carried out on 10 control males and 10 males treated with 500 ppm and necropsied at the end of treatment period. Brain tissue was embedded in paraplast and stained with haematoxylin and eosin and with cresyl violet; samples of spinal cord, peripheral nerves, ganglia and muscle were embedded in epoxy resin and stained with toluidine blue.
There were no treatment-related microscopic changes in the multiple examined areas of the central and peripheral nervous system, indicating that test substance was devoid of neuropathic effects under conditions of this special experiment. - Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- effects observed, treatment-related
- Description (incidence and severity):
- CONCENTRATION OF TEST ARTICLE IN TISSUE
The compound accumulated in fatty tissue reaching a mean concentration of 2600 mg/kg in the high dose group at the end of the treatment period. At the end of the 2-month recovery period without exposure to test article, mean concentration in fat of high-dose animals was still at 1600 mg/kg. These data indicate that test substance, is preferentially accumulated in fat and has a very slow rate of elimination.
PENTYLENETETRAZOL POTENTIATION
Following intraperitoneal injection with 25 mg/kg of pentylenetetrazol at the end of the treatment period, generalised clonic-tonic convulsions involving the hind limbs were induced in top dose animals only. Comparable motor seizures limited to the head, neck and forelimb areas were induced in all other groups. After a generalised clonic-tonic convulsion subsequent seizure activity was inhibited whereas motor seizures were shown frequently throughout the 30 minute observation period. At the end of the recovery period, incidence rate for generalised convulsions in top dose animals was comparable to that seen at the end of the treatment period. Median convulsion scores in the top dose animals were lower than at the end of the treatment period but still higher than in control animals, thus indicating partial recovery from the proconvulsive effect induced by the test article. - Key result
- Dose descriptor:
- NOAEL
- Remarks:
- systemic
- Effect level:
- 100 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- neuropathology
- Remarks on result:
- other:
- Remarks:
- Dietary equivalent to 5.43 mg/kg bw/day
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- neurotoxicity
- Effect level:
- 100 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- neuropathology
- Remarks on result:
- other:
- Remarks:
- Dietary equivalent to 5.43 mg/kg bw/day
- Key result
- Critical effects observed:
- no
- Conclusions:
- No effects of treatment with testsubstance was observed 100 ppm or below, hence 100 ppm (equivalent to 5.43 mg/kg/day) was considered to be the no observable effect level (NOEL) in this study.
- Executive summary:
The aim of the present study, performed according the OECD Draft Guideline 424≈FIFRA § 82-5 and GLP, was to characterise the neurotoxic potential of test substance by assessing changes in neurological functions, motor activity, and neuro-histopathology. In addition, maze learning, startle habituation, and potentiation of pentylenetetrazol-induced convulsions were assessed. The test substance was administered to 70 male Tif:RAIf (SPF), albino rats at dietary levels of 0, 5, 25, 100 or 500 ppm, corresponding to a dietary concentrations of 0, 0.255, 1.22, 5.43 and 27.0 mg/kg bw/day, respectively. In the study 10 males per dose group were used and an additional 10 males rats were used as recovery group in the control and high dose group.
Male rats given 500 ppm test substance for 4 months induced single episodes of spontaneous clonic-tonic convulsion or fasciculations and facilitated pentylenetetrazol-induced generalised convulsions. Neurological parameters, motor activity, startle response and startle habituation, complex spatial learning, as well as histology of the peripheral and central nervous system were not affected by treatment. The proconvulsive effect partially recovered over a 2-month period without exposure to the test substance. There were no indications for impaired motor or cognitive functions or for permanent lesions in the peripheral or central nervous system. No effects of treatment with test substance were seen at 100 ppm or below. A concentration of 100 ppm (equivalent to 5.43 mg/kg/day) can thus be considered as a no observable effect level (NOEL) in this study.
Reference
Table 1: Incidence rate for pentylenetetrazol induced convulsions (number of animals)
|
Dietary concentration of test substance (ppm) |
||||
|
0 |
5 |
25 |
100 |
500 |
Week 19 |
10 0 |
10 0 |
10 0 |
10 0 |
3 7* |
Week 27 |
9 1 |
|
|
|
4 6 |
* Statistically significant difference from control group mean, p<0.01 (Fisher’s Exact Test, 2-sided)
Table 2 Concentration in blood (mg/L) and in fat (mg/kg)
|
Dietary concentration of test substance (ppm) |
||||
|
0 |
5 |
25 |
100 |
500 |
Concentration in blood (mg/L) Week 27 |
<0.1 |
0.1 |
0.6 |
2.6 |
17 4.3 |
Concentration in fat (mg/kg) Week 28 |
<2 <2 |
16
|
150
|
660 |
2600 1600 |
* Statistically significant difference from control group mean, p<0.01 (Fisher’s Exact Test, 2-sided)
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 5.43 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- GLP compliant OECD TG 424 study.
Effect on neurotoxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Effect on neurotoxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Neurotoxicity: oral
4-month dietary study in rats
The aim of the present study, performed according the OECD Draft Guideline 424≈FIFRA § 82-5 and GLP, was to characterise the neurotoxic potential of test substance by assessing changes in neurological functions, motor activity, and neuro-histopathology. In addition, maze learning, startle habituation, and potentiation of pentylenetetrazol-induced convulsions were assessed. The test substance was administered to 70 male Tif:RAIf (SPF), albino rats at dietary levels of 0, 5, 25, 100 or 500 ppm, corresponding to a dietary concentrations of 0, 0.255, 1.22, 5.43 and 27.0 mg/kg bw/day, respectively. In the study 10 males per dose group were used and an additional 10 males rats were used as recovery group in the control and high dose group.
Male rats given 500 ppm test substance for 4 months induced single episodes of spontaneous clonic-tonic convulsion or fasciculations and facilitated pentylenetetrazol-induced generalised convulsions. Neurological parameters, motor activity, startle response and startle habituation, complex spatial learning, as well as histology of the peripheral and central nervous system were not affected by treatment. The proconvulsive effect partially recovered over a 2-month period without exposure to the test substance. There were no indications for impaired motor or cognitive functions or for permanent lesions in the peripheral or central nervous system. No effects of treatment with test substance were seen at 100 ppm or below. A concentration of 100 ppm (equivalent to 5.43 mg/kg/day) can thus be considered as a no observable effect level (NOEL) in this study.
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.